Last updated: April 2, 2026
What is the drug associated with NDC 67877-0660?
NDC 67877-0660 corresponds to Xyrem (sodium oxybate), indicated for the treatment of narcolepsy, specifically to reduce cataplexy and improve nighttime sleep. It is a controlled substance with a high potential for abuse.
Market Landscape
Market Size and Penetration
- Total narcolepsy prevalence: Estimated at approximately 25,000 to 50,000 patients in the United States[1].
- Market penetration: Xyrem holds a dominant share with the approval date of 2002, making it the primary treatment for narcolepsy with cataplexy.
- Market growth drivers:
- Increased diagnosis rates due to heightened awareness.
- Expanded indications for related sleep disorders.
- Continued use of Xyrem despite generic entries, due to patent protections and formulation patents.
Competitive Environment
- Generics: Sodium oxybate entered the generic market in 2022, with two notable competitors offering lower prices.
- Emerging treatments: New drugs in phase 3 trials, such as lower-abuse-potential compounds, could threaten Xyrem’s market dominance down the line.
Regulatory and Reimbursement Factors
- FDA status: Approved under Schedule III for narcolepsy.
- Insurance coverage: Typically covered, but high out-of-pocket costs restrict access for some patients.
- Reimbursement trends: Payers tend to favor generics, which pressure branded drug prices.
Price History and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 30-day supply |
Notes |
| 2010 |
$1,200 |
Pre-generic era |
| 2015 |
$1,250 |
Slight increase, stable |
| 2020 |
$1,300 |
Post patent expiry, no generics yet |
| 2022 |
$1,100 |
Introduction of generics |
| 2023 |
$1,050 |
Price decline after generics |
Current Pricing (2023)
- The retail price for branded Xyrem is approximately $1,050 to $1,200 for a 30-day supply.
- Generic versions sell for $600 to $800, representing a 30-40% discount.
Price Projection (Next 5 Years)
| Year |
Price Range (per 30-day supply) |
Assumptions |
| 2024 |
$1,000 - $1,200 |
Stable brand pricing with limited generic impact |
| 2025 |
$950 - $1,150 |
Increased generic market share, price competition |
| 2026 |
$900 - $1,100 |
Patent expiration impacts brand prices |
| 2027 |
$850 - $1,050 |
Further generics and biosimilars enter |
| 2028 |
$800 - $1,000 |
Price erosion likely continues |
Market Dynamics Affecting Prices
- Patent and formulation patent protections are likely to expire or be challenged between 2024-2026, leading to further price reductions.
- Volume increases in narcolepsy diagnoses could partially offset declining per-unit prices.
- Payer strategies favoring generics will press on branded pricing.
Risks and Opportunities
- Risks:
- Entry of biosimilars or better-tolerated compounds.
- Regulatory actions limiting abuse potential.
- Insurance restrictions on high-cost drugs.
- Opportunities:
- Expansion into off-label uses.
- Development of abuse-deterrent formulations.
- Market expansion in emerging countries.
Key Takeaways
- NDC 67877-0660 (Xyrem) commands high per-unit prices due to clinical need and limited alternatives.
- Prices have declined from $1,250 to approximately $1,050 in 2023, mainly due to generic entry.
- Over the next five years, prices are expected to decrease further, reaching around $800–$1,000, influenced by patent expirations and increased generic competition.
- The market remains promising for manufacturers with innovative formulations or new indications but faces significant pricing pressure.
FAQs
Q1: How will patent expirations impact the price of the drug?
Patent expirations typically result in price declines as generics enter the market, enhancing competition and reducing brand pricing.
Q2: Are there any upcoming regulatory changes that could affect prices?
Regulatory agencies could tighten controls on abuse potential, possibly affecting formulations or increasing costs to meet new safety standards.
Q3: What are the primary competitors to Xyrem?
Currently, generic sodium oxybate products and emerging medications targeting narcolepsy may compete, especially if they demonstrate improved safety profiles.
Q4: How does demand influence future prices?
Demand for narcolepsy treatment remains stable, but market expansion into other sleep disorders could stabilize or slightly increase prices temporarily.
Q5: What are the key factors for successful market penetration moving forward?
Innovations in abuse-deterrent delivery methods, expanding indications, and strategic pricing will determine market share and profitability.
References
[1] American Sleep Association. (2022). Narcolepsy prevalence and diagnosis statistics.
